Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

E2F1-Mediated Induction of NFYB Attenuates Apoptosis via Joint Regulation of a Pro-Survival Transcriptional Program.

Jiang X, Nevins JR, Shats I, Chi JT.

PLoS One. 2015 Jun 3;10(6):e0127951. doi: 10.1371/journal.pone.0127951. eCollection 2015.

2.

ASSOCIATIONS BETWEEN ULTRASOUND AND CLINICAL FINDINGS IN 87 CATS WITH URETHRAL OBSTRUCTION.

Nevins JR, Mai W, Thomas E.

Vet Radiol Ultrasound. 2015 Jul-Aug;56(4):439-47. doi: 10.1111/vru.12259. Epub 2015 Apr 8.

PMID:
25850697
3.

Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.

Rempel RE, Jiang X, Fullerton P, Tan TZ, Ye J, Lau JA, Mori S, Chi JT, Nevins JR, Friedman DR.

Mol Cancer Ther. 2014 Dec;13(12):3219-29. doi: 10.1158/1535-7163.MCT-13-0044. Epub 2014 Oct 27.

4.

Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control.

Dong P, Maddali MV, Srimani JK, Thélot F, Nevins JR, Mathey-Prevot B, You L.

Nat Commun. 2014 Sep 1;5:4750. doi: 10.1038/ncomms5750.

5.

FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.

Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins JR.

Cancer Res. 2013 Oct 1;73(19):6056-67. doi: 10.1158/0008-5472.CAN-13-0453. Epub 2013 Aug 21.

6.

Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.

Liu B, Shats I, Angus SP, Gatza ML, Nevins JR.

J Biol Chem. 2013 Aug 23;288(34):24581-9. doi: 10.1074/jbc.M113.467506. Epub 2013 Jul 13.

7.

E2F6 associates with BRG1 in transcriptional regulation.

Leung JY, Nevins JR.

PLoS One. 2012;7(10):e47967. doi: 10.1371/journal.pone.0047967. Epub 2012 Oct 17.

8.

A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest.

Angus SP, Nevins JR.

Oncogene. 2012 Nov 1;31(44):4709-17. doi: 10.1038/onc.2011.622. Epub 2012 Jan 16.

9.

Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2012 Feb 1;307(5):453. doi: 10.1001/jama.2012.2. Epub 2012 Jan 6. No abstract available.

PMID:
22228686
10.

SIGNATURE: a workbench for gene expression signature analysis.

Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P, Nevins JR.

BMC Bioinformatics. 2011 Nov 14;12:443. doi: 10.1186/1471-2105-12-443.

11.

Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.

Leung JY, Andrechek ER, Cardiff RD, Nevins JR.

Oncogene. 2012 May 17;31(20):2545-54. doi: 10.1038/onc.2011.433. Epub 2011 Sep 26.

12.

Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569. doi: 10.1073/pnas.1115170108. Epub 2011 Oct 3. No abstract available.

13.

Network calisthenics: control of E2F dynamics in cell cycle entry.

Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L.

Cell Cycle. 2011 Sep 15;10(18):3086-94. Epub 2011 Sep 15. Review.

14.

Peripheral blood signatures of lead exposure.

LaBreche HG, Meadows SK, Nevins JR, Chute JP.

PLoS One. 2011;6(8):e23043. doi: 10.1371/journal.pone.0023043. Epub 2011 Aug 1.

15.

Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors.

LaBreche HG, Nevins JR, Huang E.

BMC Med Genomics. 2011 Jul 22;4:61. doi: 10.1186/1755-8794-4-61.

16.

A methodology for utilization of predictive genomic signatures in FFPE samples.

Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR.

BMC Med Genomics. 2011 Jul 11;4:58. doi: 10.1186/1755-8794-4-58.

17.

Use of gene expression and pathway signatures to characterize the complexity of human melanoma.

Freedman JA, Tyler DS, Nevins JR, Augustine CK.

Am J Pathol. 2011 Jun;178(6):2513-22. doi: 10.1016/j.ajpath.2011.02.037.

18.

Using noisy gene expression mediated by engineered adenovirus to probe signaling dynamics in mammalian cells.

Wong JV, Yao G, Nevins JR, You L.

Methods Enzymol. 2011;497:221-37. doi: 10.1016/B978-0-12-385075-1.00010-X.

PMID:
21601089
19.

Pathway-based classification of lung cancer: a strategy to guide therapeutic selection.

Nevins JR.

Proc Am Thorac Soc. 2011 May;8(2):180-2. doi: 10.1513/pats.201006-040MS.

20.

Origin of bistability underlying mammalian cell cycle entry.

Yao G, Tan C, West M, Nevins JR, You L.

Mol Syst Biol. 2011 Apr 26;7:485. doi: 10.1038/msb.2011.19.

21.

Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.

Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR.

N Engl J Med. 2011 Mar 24;364(12):1176. doi: 10.1056/NEJMc1101915. Epub 2011 Mar 2.

22.

Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC.

Wong JV, Yao G, Nevins JR, You L.

Mol Cell. 2011 Feb 4;41(3):275-85. doi: 10.1016/j.molcel.2011.01.014.

23.

Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2011 Feb;12(2):116. doi: 10.1016/S1470-2045(11)70011-0. No abstract available.

PMID:
21277543
24.

Retraction: Genomic signatures to guide the use of chemotherapeutics.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR.

Nat Med. 2011 Jan;17(1):135. doi: 10.1038/nm0111-135. No abstract available.

PMID:
21217686
25.

Using a stem cell-based signature to guide therapeutic selection in cancer.

Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR.

Cancer Res. 2011 Mar 1;71(5):1772-80. doi: 10.1158/0008-5472.CAN-10-1735. Epub 2010 Dec 17.

26.

Stochastic E2F activation and reconciliation of phenomenological cell-cycle models.

Lee TJ, Yao G, Bennett DC, Nevins JR, You L.

PLoS Biol. 2010 Sep 21;8(9). pii: e1000488. doi: 10.1371/journal.pbio.1000488.

27.

Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles.

Meadows SK, Dressman HK, Daher P, Himburg H, Russell JL, Doan P, Chao NJ, Lucas J, Nevins JR, Chute JP.

PLoS One. 2010 Jul 12;5(7):e11535. doi: 10.1371/journal.pone.0011535.

28.

Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.

Andrechek ER, Nevins JR.

J Mol Med (Berl). 2010 Nov;88(11):1095-100. doi: 10.1007/s00109-010-0644-z. Epub 2010 Jun 24. Review.

29.

Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate.

Kim JW, Mori S, Nevins JR.

Cancer Res. 2010 Jun 15;70(12):4820-8. doi: 10.1158/0008-5472.CAN-10-0659. Epub 2010 Jun 1. Erratum in: Cancer Res. 2010 Aug 1;70(15):6397.

30.

Refocusing the war on cancer: the critical role of personalized treatment.

Potti A, Schilsky RL, Nevins JR.

Sci Transl Med. 2010 Apr 21;2(28):28cm13. doi: 10.1126/scitranslmed.3000643.

PMID:
20410527
31.

Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.

Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB.

J Clin Oncol. 2010 May 1;28(13):2198-206. doi: 10.1200/JCO.2009.26.7245. Epub 2010 Apr 5.

32.

A pathway-based classification of human breast cancer.

Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. doi: 10.1073/pnas.0912708107. Epub 2010 Mar 24.

33.

Multimodal regulation of E2F1 gene expression by progestins.

Wade HE, Kobayashi S, Eaton ML, Jansen MS, Lobenhofer EK, Lupien M, Geistlinger TR, Zhu W, Nevins JR, Brown M, Otteson DC, McDonnell DP.

Mol Cell Biol. 2010 Apr;30(8):1866-77. doi: 10.1128/MCB.01060-09. Epub 2010 Feb 1.

34.

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR.

Clin Cancer Res. 2009 Nov 15;15(22):6947-55. doi: 10.1158/1078-0432.CCR-09-1132. Epub 2009 Oct 27.

35.

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.

Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16387-92. doi: 10.1073/pnas.0901250106. Epub 2009 Sep 4.

36.

A role for E2F activities in determining the fate of Myc-induced lymphomagenesis.

Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, Laakso NM, Lagoo AS, Storms R, Smith C, Nevins JR.

PLoS Genet. 2009 Sep;5(9):e1000640. doi: 10.1371/journal.pgen.1000640. Epub 2009 Sep 11.

37.

Utilization of genomic signatures to identify phenotype-specific drugs.

Mori S, Chang JT, Andrechek ER, Potti A, Nevins JR.

PLoS One. 2009 Aug 28;4(8):e6772. doi: 10.1371/journal.pone.0006772.

38.

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM.

Breast Cancer Res. 2009;11(4):R55. doi: 10.1186/bcr2344. Epub 2009 Jul 28. Erratum in: Breast Cancer Res. 2011;13(4):406.

39.

A combinatorial mechanism for determining the specificity of E2F activation and repression.

Freedman JA, Chang JT, Jakoi L, Nevins JR.

Oncogene. 2009 Aug 13;28(32):2873-81. doi: 10.1038/onc.2009.153. Epub 2009 Jun 22.

40.

Anchorage-independent cell growth signature identifies tumors with metastatic potential.

Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR.

Oncogene. 2009 Aug 6;28(31):2796-805. doi: 10.1038/onc.2009.139. Epub 2009 Jun 1.

41.

A genomic strategy to elucidate modules of oncogenic pathway signaling networks.

Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR.

Mol Cell. 2009 Apr 10;34(1):104-14. doi: 10.1016/j.molcel.2009.02.030.

42.

Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. doi: 10.1073/pnas.0900827106. Epub 2009 Mar 11. Erratum in: Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14705.

43.

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.

Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr.

Breast Cancer Res Treat. 2009 Dec;118(3):635-43. doi: 10.1007/s10549-008-0301-1. Epub 2009 Feb 18.

44.

Balancing the decision of cell proliferation and cell fate.

Hallstrom TC, Nevins JR.

Cell Cycle. 2009 Feb 15;8(4):532-5. Epub 2009 Feb 11. Review.

45.

Genomic and molecular profiling predicts response to temozolomide in melanoma.

Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS.

Clin Cancer Res. 2009 Jan 15;15(2):502-10. doi: 10.1158/1078-0432.CCR-08-1916. Erratum in: Clin Cancer Res. 2009 May 1;15(9):3240.

46.

A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7. doi: 10.1073/pnas.0806674105. Epub 2008 Dec 2. Retraction in: Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569. Erratum in: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6878.

47.

High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics.

Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M.

J Am Stat Assoc. 2008 Dec 1;103(484):1438-1456.

48.

Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, Potti A, Bild A, Nevins JR.

Cancer Res. 2008 Oct 15;68(20):8525-34. doi: 10.1158/0008-5472.CAN-08-1329.

49.

Toward the individualization of lung cancer therapy.

Anguiano A, Nevins JR, Potti A.

Cancer. 2008 Oct 1;113(7 Suppl):1760-7. doi: 10.1002/cncr.23644.

50.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148

Supplemental Content

Loading ...
Support Center